Last updated on March 2020

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation


Brief description of study

This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence

Clinical Study Identifier: NCT03383458

Find a site near you

Start Over

Local Institution

Bunkyo-ku, Japan
0.81miles
  Connect »

Local Institution

Shinjuku-ku, Japan
2.09miles
  Connect »

Local Institution

Chuo-ku, Japan
3.23miles
  Connect »